2020 keynote speakers revealed
Three world renowned digital and technology experts from external industries will be giving keynote presentations at Animal Health Investment Europe 2020. This is a great opportunity for animal health and nutrition companies to learn from and adapt to the impacts of disruptive technologies in other sectors in a way that will drive transformative change and open new opportunities for their businesses.
Read the full speaker biographies and find out more in our keynote announcement -
Download 2020 Keynote Speaker Announcement
Why Attend?
Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutritional health, and connecting those businesses with financial investors and strategic corporate partners from 38 countries worldwide.
To complement our investment pitches, we host CEO-level discussions that address the trends and market dynamics of the animal health industry, across all species.
Networking is a large part of what we offer - across the two days you can meet face-to-face with decision makers from the full spectrum of the animal pharma and nutritional health industry: from our 200 start-ups (such as Proteon Pharma and REX Animal Health, the winners of the 2019 Innovation Showcase), to C-Suite leaders from 18 of the top 20 animal health companies (including Clint Lewis of Zoetis, Joachim Hasenmaier and Jeff Simmons of Elanco).
Book now to come and see for yourself!
Speakers
Matteo Ratti
David Hallas
Mike Ellis
Michael Ellis is the senior vice president and president of Europe at Covetrus. He has held previous positions as CFO, general manager, vice president, and president of Europe at Henry Schein Animal Health at Henry Schein. Michael is a Fellow Chartered Management Accountant, FCMA, and has a diploma in business studies from Sheffield University.
Laurie Hueneke
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Mark Heffernan
Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.
Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.
Maarten Goossens
Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management.
Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture.
Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.
David Prien
David founded FirstVet in 2016 and has previously run several pet-related startups in the Nordics, taking them from early stages to exits. Graduated from SSE with a double degree in Business & Retail Management.
Björgólfur Hávardsson
Björgólfur Hávardsson MSc, is the Innovation Manager with the Seafood Innovation Cluster, a Norwegian Centre of Expertise member based out of Bergen, Norway.
After three decades of multiple biological roles in the aquaculture industry, Mr. Hávardsson has an extensive knowledge of the biological possibilities and challenges in modern salmon farming. Through working in the industry on such diverse fields as fish counting, biomass estimation, smoltification, fish welfare, feeding systems and -behaviour as well as writing practical books on netfouling in Europe and South America, Hávarðsson is experienced in developing and presenting ideas and practical methods through courses, presentations and articles in several languages.
Mr. Hávardsson holds a Master´s degree in Aquaculture Biology from the University of Bergen (UIB) and a degree from an executive program in Strategy and Branding in the seafood industry from the Norwegian School of Economics (NHH).
Alexis Nahama
Linda Dixon
Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.
Linda’s group has focussed on research underpinning the development of effective vaccines. Their approach has been to determine genome sequences of virulent and attenuated (weakened) isolates to help define the molecular determinants of virulence and identify those genes involved in evading host defences. The group has characterised ASFV proteins that inhibit host pathways involved in activating the host’s defences. These include proteins that inhibit host gene expression (transcription) responses, signal molecule induction and stress-activated responses. This knowledge has been applied to the rational development of candidate live attenuated ASFV vaccines by targeted gene deletions.
In collaboration with the Vaccinology Group they have compared host responses in vitro (in glass) and in vivo (in animal) and induction of protective immune responses in pigs immunised with these gene manipulated and natural attenuated ASFV strains. The group has also collaborated with these groups and The Jenner Institute to screen ASFV antigens for those important in induction of protective immunity, in particular those which induce strong immune (CD8+ T cell) responses. This information will be applied to development of candidate virus-vectored vaccines.
In addition Linda provides advice on ASFV nationally to Defra and internationally as an OIE expert and is Chair of the Asfarviridae Study Group of the International Committee on Taxonomy of Viruses and a Jenner Institute Investigator.
Justin Sherrard
As Global Strategist Animal Protein, Justin Sherrard is responsible for the timely and agenda-setting analysis of issues of strategic importance to animal protein companies around the world.
In his research and client engagement, Justin focusses on business opportunities in animal protein through, for example, increased production efficiencies, better access to growth markets and stronger supply chain models.
Prior to his current role, Justin has worked at RaboResearch Food & Agribusiness as Global Manager Research, Global Strategist F&A Supply Chains, and General Manager of Food & Agribusiness Research for Rabobank in Australia and New Zealand. He joined Rabobank in 2009.
Justin has also worked as an independent advisor to leading blue chip companies, not-for-profit organisations and governments, applying his knowledge of food & agribusiness, energy and natural resources issues, including sustainability and climate change.
Justin has over 20 years of global experience having worked in Europe, the United States, Latin America, New Zealand as well as his native Australia. He holds a Master of Applied Science and Bachelor of Science from the University of New South Wales in Sydney, Australia.
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Jo Malone
Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.
In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.
In 2015 she became Managing Director of VetPartners and then CEO in 2016.
Dave Ross
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University
Marc de Beer
Dr. Silke Birlenbach
Michael Helmstetter
Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).
TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.
Michael also serves as Managing Partner of Covenant Animal Health Partners, a TechAccel subsidiary that focuses on development of “revenue-ready” animal health products for both companion and farm animals.
Before founding TechAccel, Michael served as the fifth President and Chief Executive Officer of MRIGlobal – one of the nation's most prominent research institutions. In his 14 years with MRIGlobal (formerly Midwest Research Institute), he led its growth from 2 to 17 national and international locations.
Michael has more than 30 years of experience working with the private sector and government agencies, including laboratory management positions at Applied Marine Research Laboratory in Norfolk, Va., and program management for the Harbor Branch Oceanographic Institution in Fort Pierce, Fla. He was President and Chairman of startup Brevard Teaching and Research Laboratories, a post he held until the company was acquired by MRIGlobal.
Michael received a Ph.D. in Chemical Toxicology/Oceanography from Old Dominion University and a B.S. in Biology from Allegheny College. He has been a panelist, keynote speaker, lecturer, reviewer to several journals, and is the author of numerous publications, articles, book chapters, and technical reports.
He has served on several boards, including Labconco Corp. Board of Directors and University of Missouri-Kansas City Board of Trustees, as well as numerous civic organizations. He is a contributing opinion writer for Forbes.com.
Michael lives in suburban Kansas City.
Email: [email protected]
LinkedIn www.linkedin.com/in/michaelhelmstetter/
Spencer Swayze
Todd B. Richter C.F.A
Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays. From 1999 to 2016 Todd Richter was a Senior Managing Director in the Global Healthcare Corporate & Investment Banking Group at Bank of America Merrill Lynch. From 1981 to 1999, Mr. Richter served as the head of the healthcare services analytical team for Morgan Stanley. Todd Richter earned a B.B.A. in Finance from the College of William & Mary in 1979 and an M.B.A. in Finance with Honors from Indiana University in 1981. Todd was recognized 16 times as a member of the Institutional Investor’s All-America Research Team. He was also listed many times among the Wall Street Journal’s “All-Star” analysts and on the Reuters research poll. Mr. Richter is currently a member of the Board of Directors (Vice Chairman) of Bideawee, one of the nation’s leading animal rescue organizations; a member of the Board of Directors at the Stratton Mountain School (SMS) in Stratton, Vermont, a member of the Board of Directors at Animal Lighthouse Rescue (ALR), and a member of the Dean’s Council for the Kelley School of Business at Indiana University. Finally Mr. Richter is on the Board and faculty of the Columbia University Mailman School of Public Health teaching a course on healthcare consolidation to MPH and MHA candidates.
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Mark Heffernan
Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.
Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.
Malcolm Thomas
Dino Dedic, CFA
Jason Cleaversmith
Jason Cleaversmith is now an Independent Aquaculture Expert. He joined the Scottish Aquaculture Innovation Centre (SAIC) in April 2015 with a mandate to help transform the relationship between Industry and Academia, whilst concurrently facilitating economic growth for the Aquaculture Sector.
Prior to joining SAIC he was the Head of the Novartis Aqua Health presence on Prince Edward Island, Canada where he oversaw 4 facilities, 125 staff and both R&D and Manufacturing related activities. Before joining Novartis, Dr. Cleaversmith led the Bioscience portfolio on behalf of the Province of Prince Edward Island and was responsible for the growth and economic development of the cluster by way of both inward investment and existing company growth.
His career spans time in Blue Chip organizations through to frontline SME positions in roles such as Business Development Director and Head of Operations. In addition, he was a member of the Executive at the Scottish Association for Marine Science and ledfrom inception the development of their commercial subsidiary and technology / knowledge transfer activities, including the building and population of the European Centre for Marine Biotechnology. Subsequently he has worked within the marine biotechnology sector, focusing on natural product discovery for the nutri-, cosme- and pharmaceutical sectors.
He is a Fellow of the Royal Society of Biology, Chartered Manager and is a member of the Institute of Directors. Prior voluntary positions include chair of the board for the University of Prince Edward Islands technology transfer office (Synapse), Vice Chair of the PEI BioAlliance and participated on the steering committee for the biotechnology program at Holland College.
Jason is a graduate of Edinburgh University, Scotland, with a major in Geology followed by a PhD in Marine Geochemistry and has subsequently completed an Executive MBA with the University of Glasgow, where he gained a Distinction.
Mark Boddy
Bruce Whitelaw
Tim Starzl
Sébastien Lafon
Peter McCarthy
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.
Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.
Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.
Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
Torben Gosvig Madsen
Dr. Madsen started his career at Evonik Animal Nutrition in 2003 as a technical sales manager covering Scandinavia. In 2007 he was transferred to Singapore where he first headed the technical service team in Asia South (Sub-Continent, South East Asia, and Oceania) and later in 2010 promoted to Sales Director for Evonik’s feed additives sales team in this region. In 2013 Torben Madsen moved to Germany where he took the position as Vice President Global Account at Evonik Animal Nutrition. In 2014 he moved back to Asia to head the Animal Nutrition team in Asia North. Since Oct this year Torben has been heading the Product line Sustainable Health Nutrition. In this position he is responsible for developing and executing the growth strategies for the Gut Health Solutions, Aquaculture and Ruminant business at Evonik Animal Nutrition.
Torben holds a Ph.D. in ruminant physiology from the Agricultural University of Copenhagen, Denmark. Before he joined Evonik in 2003 he worked as an assistant professor at the Agricultural University of Copenhagen. He has a long publication list in peer reviewed scientific journals as well as popular agricultural magazines.
Deborah Dullen
Thomas Farrugia
Dawn Howard
Morten Nordstad
Joseph Harvey
Paul Finnerty
Dr. Lawrence Brown
Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.
Sarai Kemp
As VP Business Development for Trendlines Agrifood (Israel) since 2012 and VP Deal Flow for the Trendlines Agrifood Fund (Singapore), Sarai Kemp is responsible for sourcing start-ups, evaluating opportunities, negotiating, and closing investments and working with portfolio companies post-investment. Sarai is a board member on Hargol FoodTech, AgroScout, FruitSpec and AlgaHealth.
Sarai brings more than 20 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.
Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.
Dganit Vered
Laurent Genet
Franco Sturla
Robert Kelly
Shane Kelly
Apply for the 2020 innovation Showcase
Applications for the innovation showcase have now closed. You can download the finalist announcement in the resources section below.
What's new for 2020?
This year, 20 emerging companies will present in two separate showcases that will run across the show:
10 start-ups will present their innovations in the companion animal & pet care space.
10 start-ups will present their innovations in the production animal & animal agri-tech space.
Showcase applicants are eligible for a discounted ticket to come and meet the investors face-to-face.
Series Highlights
Photo Gallery
Photos from February 2019 are now available to download and share - view the full photo gallery here.
Advisory Board
Author:
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Author:
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Author:
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Author:
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Author:
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Author:
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Author:
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Selection Committee
Author:
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Author:
Matthias Hofer
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Author:
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Author:
Maarten Goossens
Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management.
Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture.
Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.
Author:
Sarai Kemp
As VP Business Development for Trendlines Agrifood (Israel) since 2012 and VP Deal Flow for the Trendlines Agrifood Fund (Singapore), Sarai Kemp is responsible for sourcing start-ups, evaluating opportunities, negotiating, and closing investments and working with portfolio companies post-investment. Sarai is a board member on Hargol FoodTech, AgroScout, FruitSpec and AlgaHealth.
Sarai brings more than 20 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.
Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.
Author:
Paul Dick
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Author:
Isaac Fraynd
Isaac tracks over a thousand investment opportunities, moving them through our dealflow process when appropriate. Prior to Aqua-Spark, Isaac worked as an Investment Banking Analyst at Deutsche Bank’s New York office on market analysis, financial modelling, valuation scenarios, and deal execution. Isaac worked within the Latin America Group, across sectors, primarily focusing on Mergers & Acquisitions. Isaac is from Panama City, Panama and holds a Bachelor of Science in Economics as well as a certificate in Energy and the Environment from Duke University. He is very passionate about travel and is a self-declared foodie.
Author:
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
The Agenda
You can download our latest agenda here.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Download the 2020 Agenda
Partners
Animal Health Investment Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.
Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health Investment series.
Headline Partner
MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com/ or connect with us on LinkedIn and Twitter.
Associate Partners
Elanco
Website: http://www.elanco.com
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.
GHO Capital
Website: http://ghocapital.com
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare private equity firm based in London. GHO Capital works with ambitious management teams of profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. The Firm’s 2015 vintage fund – GHO Capital Fund I LP – has been raised to seize the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment and industry skills which sets the Firm apart from traditional private equity firms. For further information, please visit www.ghocapital.com.
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Boehringer Ingelheim
Website: http://www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
IDEXX
Website: http://www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Knowledge Partner
McKinsey & Company
Website: https://www.mckinsey.com
McKinsey & Company is a global management consulting firm committed to helping organizations create Change that Matters.
In more than 130 cities and 65 countries, our teams help clients across the private, public and social sectors shape bold strategies and transform the way they work, embed technology where it unlocks value, and build capabilities to sustain the change. Not just any change, but Change that Matters – for their organizations, their people, and in turn society at large.
Senior Event Partners
Proteon Pharmaceuticals
Website: http://www.proteonpharma.com
PROTEON uses bacteriophages as the foundation for preventing and eradicating infectious diseases in animals, humans and plants. Bacteriophages are naturally occurring organisms in the microbiome.
Bacteriophages offer an exciting alternative to antibiotics in combating pathogenic bacteria including antibiotic resistant microbes (AMR). PROTEON’s therapeutic products are safe for human, animals and plants and are based on environmentally sustainable methods and approaches.
We have developed a unique phage-platform using proprietary tools and expertise in microbiology, DNA sequencing and bioinformatics. Our phage-platform enables continued discovery of new solutions for a wide variety of industries and applications.
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Nutreco NuFrontiers
Website: http://www.nutreconufrontiers.com
Nutreco is a global leader in animal nutrition and aquafeed. Our advanced nutritional solutions are at the origin of food for millions of consumers worldwide. Nutreco employs over 12,000 people in 35 countries with net sales of over € 6 billion. Our two global company brands Skretting (aquafeed) and Trouw Nutrition (animal nutrition) have sales in over 90 countries. Innovation sits at the very heart of Nutreco’s business and culture. Through our strategic innovation and investment division Nutreco NuFrontiers, we look to identify, develop and invest in next generation, sustainable products, models and services throughout the feed and food protein value chain. NuFrontiers invests both in start-ups developing new technologies, ingredients or formulations, and joint-ventures and partnerships to create ‘moonshot projects’ that address major bottlenecks in the feed and food value chain. For more information visit www.nutreco.com and www.nutreconufrontiers.com
Evonik Animal Nutrition
Website: https://animal-nutrition.evonik.com/
Evonik is a world-leading specialty chemical company. In 2018, its more than 32,000 employees generated sales of €13.3 billion. Its Animal Nutrition business line is active in the food and animal feed market.
There is no single silver bullet when it comes to feeding future generations. It will take a concerted effort involving a wide range of partners with a ‘can-do’ attitude.
Evonik sees the task of feeding growing populations not as an imminent food crisis, but rather as a ‘global food challenge’. To help meet this challenge, customers ordering its products receive more than just feed additives – they also get a combination of customized solutions, services and digital tools.
Evonik combines science-based expertise in all aspects of animal production with intelligent software algorithms and consistent connectivity. This blends the main areas of animal nutrition, animal health, and animal farming. This approach includes Precision Livestock Farming (PLF) which adds advanced technologies and software to the farming process, with the goal of optimizing the contribution per animal.
In short, Evonik is ‘Sciencing the global food challenge’.
Paine Schwartz Partners
Website: https://www.paineschwartz.com/
A global leader in sustainable food chain investing, Paine Schwartz Partners is a private equity firm focused exclusively on investment opportunities in the fast-growing, dynamic global food and agribusiness sectors. The firm's investment, operations and finance professionals invest throughout cycles across the food and agribusiness value chain, and bring a collaborative and active management approach to portfolio companies. For further information, please see www.paineschwartz.com.
Syngene
Website: http://www.syngeneintl.com
Syngene International Ltd. is an innovation focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000- strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speedup time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.
Consulting Partner
Stonehaven Consulting
Website: http://www.stonehaven-consulting.com
Stonehaven Consulting AG was founded in 2015 as a specialist Life Science management consultancy firm. Based in Switzerland, we provide international consulting services to all sectors in Life Sciences.
We are especially interested in assisting ambitious clients wishing to commercialise new technologies or leverage opportunities for growth. We do this by following a unique approach where we not only help our clients to develop the best possible strategy but partner with them to bring it to life – we are happy to share risks and opportunities. We are an experienced group of individuals with a long track record of successful operational and strategic management on many levels and for a number of multinational Animal Health companies as well as companies in Life Sciences.
Our founder, George Gunn has served as CEO for a number of companies and our other members of the team bring complementary skills and experience to our group. All of us have substantial experience and background in Animal Health – an industry we are very excited about.
Event Partners
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
The Department for International Trade (DIT)
Website: https://www.great.gov.uk/
The Department for International Trade (DIT) helps businesses export and grow into global markets. We also help overseas companies locate and grow in the UK - our services are provided in over 100 markets throughout the world.
We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
We are an international economic department, responsible for:
- bringing together policy, promotion and financial expertise to break down barriers to trade and investment, and help businesses succeed
- delivering a new trade policy framework for the UK as we leave the EU
- promoting British trade and investment across the world
- building the global appetite for British goods and services
Paul Dick and Associates (PDA)
Website: http://pauldickassociates.com
Paul Dick & Associates Ltd. (PDA), founded in 2010, is an animal health consulting firm specializing in (1) the creation of strategic business and product life plans, (2) product development and regulatory affairs strategies, (3) the conduct of GCP studies, (4) the development of white papers to support marketing and sales, (5) business development and fundraising, (6) the acquisition and pitching of new technologies, actives and products, and, (7) various other supporting activities for product development and commercialization. The capabilities of Paul Dick & Associates Ltd. span the research, development, regulatory, and, commercialization continuum for animal pharmaceuticals, biologicals, vaccines, feed ingredients and feeds, and natural/ low risk health products. PDA is the recognized expert for these matters in Canada, as well as for other global markets.
Animalcare Group
Website: https://www.animalcaregroup.com/
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition
Phibro Animal Health Corporation
Website: http://www.pahc.com
Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal protein. We are a global diversified animal health and mineral nutrition company. We concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. For nearly 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition.
Triveritas
Website: http://www.triveritas.com
Triveritas is a veterinary CRO with local offices in Europe and North America providing assistance in the development and registration of biological and pharmaceutical products in Animal Health. With a global customer base, both start-up and Top 10 Animal Health companies count amongst returning customers. Regulatory Affairs services, from initial strategic advice to final submission of dossiers, are provided by a highly competent team, including biologicals and pharmaceuticals specialists, a toxicologist, CMC/Part II experts and Qualified Persons for Pharmacovigilance. An integrated approach to project management has lead to proven success in the approval of products at EMA, FDA, USDA and EPA. Clinical Studies, compliant to VICH GCP, are performed by fully trained, experienced Monitors, veterinarians, data managers and support scientists, together with collaborating Investigators and laboratories. Independent Quality Assurance auditors provide inspection services in VICH GCP/GLP/GMP.
Vetio Animal Health
Website: https://vetio.com/
As a Contract Development and Manufacturing Organization (CDMO) dedicated to Animal Health, Vetio integrates product development, analytical services, technical services, and commercial manufacturing of veterinary pharmaceuticals using a Quality-by-Design approach. Vetio is your single-source partner for successful product approval, scale-up, and ongoing commercial supply.
Vetio has provided expertise to animal health companies around the world since 2001 and is committed to the development and manufacturing of products that improve the lives of animals, while assuring the safety, quality and compliance of our products to the highest industry standards.
Ask Us about our intellectual property in pharmaceutical soft chews and palatability. Please visit www.vetio.com and watch our brief company overview video.
Ceva
Website: http://www.ceva.co.uk
Ceva Santé Animale (Ceva) is one of the fastest growing top 10 veterinary healthcare companies. We research, develop and produce vaccines and pharmaceutical products for poultry, companion animals, livestock and swine.
Ceva has been directly present in China for over 15 years and is heavily invested through R&D partnerships and local production of vaccines.
Ceva Huadu, Beijing focuses on poultry vaccine production and the recently formed Ceva Ebvac, Hangzhou City, will drive the rapidly expanding swine vaccine business
Since 2011, Ceva has entered into a number of scientific cooperation agreements (South China Agricultural University (SCAU), University of Beijing) designed to share knowledge and ensure that the company’s international poultry and swine expertise can be applied to local conditions in China.
Globally, Ceva is one of the leading poultry healthcare suppliers having driven innovation in hatchery vaccination, to improve efficiency and performance. Ceva’s C.H.I.C.K programme was the first hatchery services programme to be independently approved by the international standards company, Bureau Veritas. Demonstrating the company’s commitment to help its customers to constantly enhance their productivity through different means of innovation.
In swine, the company has a balanced portfolio of vaccine and pharmaceutical products that are also supported by extensive veterinary and technical services programmes (Lung programme, Respinomics).
Our growth in China, reflects the entrepreneurial nature of Ceva, which is owned and managed by its senior management team. 40% of our growth has come from the more than 30 acquisitions and innumerable license agreements that we have made since 2000. As a result, we are always open to receiving innovation proposals to generate growth in China and beyond.
OCR
Website: http://www.oncovet-clinical-research.com
OCR is a full-Vet CRO based in Lille-France, with a know-how on every steps of the clinical development and registration of a product for the pets market. OCR is specialized in clinical studies on severe diseases affecting dogs and cats: cancer, and others diseases in therapeutic areas like inflammation, cardiology, dermatology, antibiotic resistance, neurology. Along with a highly experienced team (clinical project leaders, RCA, data managers, biostatisticians, and veterinary specialist consultants), OCR built a European network of veterinary clinics with high level technical platform, including imaging (CT-scan, MRI, scintigraphy) and radiation therapy units and vet specialist strongly involved in clinical research. Our expertise in a nutshell: conception of the study with vet experts, determining pre-clinical and clinical development plans, conducting Proof-of-Concept studies, Pilot and Pivotal studies, site selection, laboratory identification and management, regulatory affairs, data management & biostatistics, VICH GCP clinical studies standards. Strong track record with the vet industry with pilot/pivotal studies, as well as with biotech/pharma through comparative medicine studies.
Anterra Capital
Website: http://www.anterracapital.com
We are a specialist venture capital investor dedicated to financing the growth of companies operating in the food & agricultural sectors
We invest across the food supply chain in technology driven companies
We focus on companies headquartered in Europe or North America although we will consider companies in other geographies
At the time of our investment our companies are typically generating revenue and have great growth prospects
We invest up to USD 20m in equity per company taking a significant minority ownership position
We are active in the boards of portfolio companies working alongside management teams to build lasting value
As a sector specialist we pride ourselves on our ability to add value in ways that generalist investors can't even dream of
Royal College of Veterinary Surgeons (RCVS)
Website: http://www.rcvs.org.uk
Royal College of Veterinary Surgeons. Setting, upholding and advancing the educational, ethical and clinical standards of veterinary surgeons and veterinary nurses.
ViAqua Therapeutics
Website: https://www.viaqua-t.com/
ViAqua currently addresses one of the most prevalent and devastating issues that plague the aquaculture industry – viral infections.
Their first solution supports the primary defenses of shrimp from environmental threats. It also acts to improve the shrimp ability to resist pathogens and prevents viral epidemic in shrimp aquaculture.
Viral pathogens account for more than 60% of disease-associated losses and more than US$3 billion of losses in global shrimp production annually.
ViAqua has developed the first orally-administered, non-GMO, non-antibiotic technology, to significantly improve shielding of a shrimp from viral infections in aquaculture, and reduce the potential of release of viruses to infect other shrimp.
The company is on track to commercialization by early 2021 and is working on applying its technology to other pathogens across various aquatic species.
ViAqua is backed by Nutreco, a world leader in animal nutrition and aquaculture feed, VisVires New Protein, one of Asia’s largest Agrifood funds, and Israeli incubator, Trendlines.
ZENOAQ
Website: http://www.zenoaq.jp/english/index.html
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
Media Partners
Agri-EPI Centre
Agri-EPI Centre is one of the four Agri-Tech Centres of Agricultural Innovation, a unique collaboration between UK Government, academia and industry to drive greater efficiency, resilience and wealth across the agri-food sector. A £90 million investment from the UK’s strategic innovation agency, Innovate UK, is enabling the four centres to harness leading UK research and expertise as a well as build new infrastructure and innovation.
Animal Pharm | IHS Markit
Website: http://www.animalpharmnews.com
The only source of animal health and animal nutrition news and analysis you’ll ever need.
Animal Pharm gathers intelligence from across the animal health and animal nutrition industries. It keeps you abreast of critical developments, emerging trends, and changes to the business, regulatory and competitive environment.
We have been providing animal health professionals worldwide with news, analysis and insight for over 30 years, and cover the food producing animal and companion animal sectors. With extensive information on animal health products including antiparasitics, vaccines, pharmaceuticals, feed, feed additives and equipment.
Features include:
Analysis of business and company news
Reporting on key players in the industry
Market developments and trends
Analysis of the latest global regulatory changes
News on product research and development
Expert opinion and analysis
One Health
Website: https://onehealthplatform.com/
The One Health Platform is a scientific reference center and a network of One Health stakeholders. We are an independent, international not-for-profit organization that fosters science for the greater good.
VetRecord
Website: https://veterinaryrecord.bmj.com/
Vet Record is the official journal of the British Veterinary Association (BVA) and has been published weekly since 1888. It contains news, comment, letters and clinical research papers on a wide range of veterinary topics. Its classified advertisement section includes an extensive list of veterinary and veterinary-related jobs.
IAHJ - International Animal Health Journal
Website: http://www.animalhealthmedia.com
IAHJ - International Animal Health Journal is a Peer reviewed by our carefully selected editorial advisory panel, and extensive research network, IAHJ reports on Regulations & Validation, Drug Discovery, Development & Delivery, Clinical Research, Nutrition & Infectious Diseases, Custom & Contract Manufacturing, Primary & Secondary Packaging, Logistics & Supply Chain Management, and Marketing & Authorisation of all Drugs, Devices and Food Products that are used in the treatment of animals.
Become a Partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Press Partnerships
Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:
- Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
- Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
- Provide one free press pass to attend
- Distribute promotional materials at the conference
If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:
Sarah Rowlands
Marketing Manager
T: +44 (0)203 696 2920
E: sarah.rowlands[@]kisacoresearch.com
Venue
Etc.venues 133 Houndsditch, London, UK
Great news! With over 430 people at the event this February, Animal Health Investment Europe has outgrown its usual venue. For 2020 we will be moving to another great central London location near Liverpool Street station:
Etc.venues 133 Houndstitch
London
EC3A 7BX
The Tower Hotel, St Katherine’s Way, London E1W 1LD (0.8 mile from etc Houndsditch)
Rate: £160.00 includes vat and English breakfast
To book: call + 44 (0) 207 523 5063 or
Email: [email protected]
Quote block ref: KISA230220FC
Book by: 26 January 2020
ACCOMMODATION
Clayton Hotel
10 Drum St, London E1 7AT (0.4 mile from etc Houndsditch)
Rate: £195.00 includes vat & breakfast
To book a room please email: [email protected]
When booking, quote reference KISACO-7280763
Please book by 26th January 2020
Visit website for more details.
The Tower Hotel
St Katherine’s Way, London E1W 1LD (0.8 mile from etc Houndsditch)
Rate: £160.00 includes vat and English breakfast
To book a room please call + 44 (0) 207 523 5063
Or email: [email protected]
When booking, quote reference KISA230220FC
Please book by 26th January 2020
Visit website for more details.
Holiday Inn Whitechapel
5 Cavell St, London E1 2BP (1.1 mile from etc Houndsditch)
23rd February - £110.00 inc vat & English breakfast
24th February - £150.00 inc vat & English breakfast
25th February - £189.00 inc vat & English breakfast
To book online click here and quote: GA1 Limited KISACO
Please book by 24th January 2020
Visit website for more details.
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.